HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Cengiz Gebitekin Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gebitekin, C. Articles by Balaban, S. A Search for Related Content PubMed PubMed Citation Articles by Gebitekin, C. Articles by Balaban, S. A

Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer

Cengiz Gebitekin, MD, Ahmet S Bayram, MD, Berrin Tunca¹, adiman A Balaban²

Department of Thoracic Surgery
¹ Department of Medical Biology and Genetics
² Department of Pathology, Uludag University, School of Medicine Bursa, Turkey

For reprint information contact: Ahmet S Bayram, MD, Tel: 90 224 442 9166, Fax: 90 224 442 8698, Email: asbayram2{at}yahoo.com, Uludag University, School of Medicine, GKDC-ABD Bursa 16059, Turkey.

In the early stage, long-term survival with non-small cell lung carcinoma has never been ideal. The aim of this study was to compare pathologically proven N0 lymph nodes obtained during mediastinoscopy with p53 gene mutation, and to correlate these with postoperative recurrence. Thirty patients undergoing mediastinoscopy for staging of non-small cell lung carcinoma were studied prospectively. Standard cervical mediastinoscopy was performed in all cases, and the specimens were divided into two pieces for histopathological and genetic investigations. All but one of the patients were male, and the mean age was 61.2 years (range, 42–74 years). Although the histopathology was negative in all cases, p53 gene mutation was observed in 6 (20%) patients. Recurrence was detected in 3 patients who had negative histopathology but were positive for p53 mutation, and in one who had negative histopathology and no p53 mutation. Patients with pathologically N0 disease and p53 gene mutation must be carefully monitored for local recurrence or distant metastasis. Neoadjuvant and/or adjuvant therapies may be considered in this group of patients.